Literature DB >> 26573000

Dual use of E-cadherin and D2-40 immunostaining in unusual meningioma subtypes.

E Kelly S Mrachek1, David Davis1, B K Kleinschmidt-DeMasters2.   

Abstract

OBJECTIVES: Meningiomas usually can be readily diagnosed on H&E alone, although occasionally immunohistochemistry (IHC) confirmation is desirable. Studies exploring the diagnostic utility of either podoplanin (D2-40) or E-cadherin IHC in meningiomas have conflicted, and no studies exist in which the two IHCs have been used in combination for diagnosis.
METHODS: E-cadherin and D2-40 IHC was performed on 77 meningiomas (31 ordinary; eight microcystic; four rare myxoid; six metaplastic; six invasive of orbit, muscle, and/or soft tissue; two metastatic; six brain-invasive World Health Organization [WHO] grade II, nine non-brain-invasive WHO grade II; and five anaplastic WHO grade III), with semi-quantitative scoring on a three-tier scale (0, focal [1+], strong/diffuse [2+]).
RESULTS: All meningiomas were either E-cadherin or D2-40 IHC+, with 69 of 77 showing dual immunostaining, most at the 2+ level. No downregulation of E-cadherin IHC was found in invasive or high-grade meningiomas.
CONCLUSIONS: Dual E-cadherin/D2-40 IHC can supplement diagnosis of meningioma. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Anaplastic meningioma; Immunohistochemistry; Invasive meningioma; Microcystic meningioma; Myxoid meningioma

Mesh:

Substances:

Year:  2015        PMID: 26573000     DOI: 10.1309/AJCPSULJ6DW5REHR

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  1 in total

1.  e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease.

Authors:  Samuela Cataldi; Michela Codini; Stéphane Hunot; François-Pierre Légeron; Ivana Ferri; Paola Siccu; Angelo Sidoni; Francesco Saverio Ambesi-Impiombato; Tommaso Beccari; Francesco Curcio; Elisabetta Albi
Journal:  Mediators Inflamm       Date:  2016-04-17       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.